Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 9/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9763870 | 1.00 | HMGCR (0.52) | HMGCR | |
| SCHEMBL1660811 | 1.00 | HMGCR (0.52) | HMGCR | |
| SCHEMBL9763539 | 1.00 | HMGCR (0.52) | HMGCR | |
| SCHEMBL9763505 | 1.00 | HMGCR (0.52) | HMGCR | |
| SCHEMBL9763877 | 1.00 | HMGCR (0.52) | HMGCR | |
| SCHEMBL1660810 | 1.00 | HMGCR (0.52) | HMGCR | |
| SCHEMBL4901679 | 0.91 | HMGCR (0.52) | HMGCR | |
| SCHEMBL4020685 | 0.91 | HMGCR (0.52) | HMGCR | |
| SCHEMBL14544900 | 0.91 | HMGCR (0.52) | HMGCR | |
| SCHEMBL9274196 | 0.91 | HMGCR (0.52) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5004747-A | Isoquinolinones | MAY & BAKER LIMITED (GB) | 1991-04-02 | — | — | US | claimed |
| EP-1406660-B1 | COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND AN HMG COA REDUCTASE INHIBITOR | PHARMACIA CORP (US) | 2007-06-06 | — | — | EP | disclosed |
| US-20060003975-A1 | Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor | PHARMACIA CORPORATION | 2006-01-05 | — | — | US | disclosed |
| CN-1537019-A | Medical combination of aldosterone receptor antagonist and HMG CoA reductase inhibitor | �ź㴫 | 2004-10-13 | — | — | CN | disclosed |
| US-6264938-B1 | ADMINISTERING POLYDIALLYLAMINE AND HYDROXY-3-METHYLGLUTARYL/3-/, COENZYME A REDUCTASE | GELTEX PHARMACEUTICALS, INC. | 2001-07-24 | — | — | US | disclosed |
| WO-2000069446-A1 | COMBINATION THERAPY FOR TREATING HYPERCHOLESTEROLEMIA | GELTEX PHARMACEUTICALS, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
| CN-1255864-A | Combination of ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors | SEARLE & CO (US) | 2000-06-07 | — | — | CN | disclosed |
| EP-0971744-A2 | COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998040375-A2 | COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-09-17 | — | — | WO | disclosed |
| US-5004747-A | Isoquinolinones | MAY & BAKER LIMITED (GB) | 1991-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003975-A1 | Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor | HMGCR, NR3C2, LDLR | HMGCR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.